During 2023, we have witnessed several significant business deals involving Antibody-drug conjugates (ADC), both in preclinical and clinical phase. This…
San Francisco (www.aktiencheck.de) - Rating-Update:
Die Analysten von Wells Fargo Advisors bekräftigen das Rating "overweight" für die Aktie von AbbVie Inc.…